Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | CTSV | O60911 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.46 |
| ▸ | ANO2 | Q9NQ90 | 1/20 | 0.46 |
| ▸ | MYC | P01106 | 1/20 | 0.45 |
| ▸ | MAX | P61244 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7912218 | 0.89 | CYP19A1 (0.51) | ALDH1A1MAPTCTSVCTSLCYP19A1 | |
| SCHEMBL16392514 | 0.88 | ALDH1A1 (0.54) | ALDH1A1MAPTCTSVCTSLCYP19A1 | |
| SCHEMBL16960692 | 0.86 | CYP19A1 (0.51) | ALDH1A1MAPTCTSVCTSLCYP19A1 | |
| SCHEMBL729587 | 0.85 | CYP19A1 (0.51) | ALDH1A1MAPTCTSVCTSLCYP19A1 | |
| SCHEMBL17202413 | 0.85 | ALDH1A1 (0.48) | ALDH1A1MAPTCTSVCTSLHTT | |
| SCHEMBL7564264 | 0.84 | HTT (0.53) | ALDH1A1MAPTCTSVCTSLCYP19A1 | |
| SCHEMBL5133112 | 0.84 | TP53 (0.50) | ALDH1A1MAPTCTSVCTSLHTT | |
| SCHEMBL1671926 | 0.83 | CTSV (0.60) | ALDH1A1MAPTCTSVCTSLHTT | |
| SCHEMBL8940873 | 0.83 | KMT2A (0.63) | ALDH1A1MAPTCTSVCTSLHTT | |
| SCHEMBL10024459 | 0.82 | HTT (0.45) | ALDH1A1MAPTCTSVCTSLHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108929263-B | Arylamide Kv2.1 inhibitor and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2022-07-22 | — | — | CN | disclosed |
| CN-111108092-A | Arylamide Kv2.1 inhibitor and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2020-05-05 | — | — | CN | disclosed |
| CN-108929263-A | Aryl amide Kv2.1 inhibitor and preparation method thereof, pharmaceutical composition and purposes | 中国医学科学院药物研究所 | 2018-12-04 | — | — | CN | disclosed |
| CN-104211635-A | Piperidine compounds, and preparation method, pharmaceutical compositions and use thereof | SHANGHAI INST MATERIA MEDICA | 2014-12-17 | — | — | CN | disclosed |
| US-8450506-B2 | Compounds and their salts specific to the PPAR receptors and the EGF Receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2013-05-28 | — | — | US | disclosed |
| US-8450506-B2 | Compounds and their salts specific to the PPAR receptors and the EGF Receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2013-05-28 | — | — | US | disclosed |
| CN-101243043-B | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INT LTD | 2013-03-20 | — | — | CN | disclosed |
| EP-1910275-B1 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | NOGRA PHARMA LTD (IE) | 2013-02-13 | — | — | EP | disclosed |
| US-20120316230-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | GIULIANI INTERNATIONAL LIMITED (IE) | 2012-12-13 | — | — | US | disclosed |
| US-20120316230-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | GIULIANI INTERNATIONAL LIMITED (IE) | 2012-12-13 | — | — | US | disclosed |
| US-20090118357-A1 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INTERNATIONAL LIMITED (IE) | 2009-05-07 | — | — | US | disclosed |
| CN-101243043-A | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INT LTD (IE) | 2008-08-13 | — | — | CN | disclosed |
| EP-1910275-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | Giuliani International Limited (IE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007010514-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | GIULIANI INTERNATIONAL LIMITED (IE) | 2007-01-25 | — | — | WO | disclosed |
| US-20020137736-A1 | N-(4-methoxy-3-((methylamino)methyl)phenyl)-2 -thiophenecarboximidamide, for example; nitric oxide synthase inhibitors; treating hypoxia, ischemia, stroke, Parkinson's disease, anxiety, schizophrenia, migraine and pain | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | disclosed |
| US-20020137750-A1 | Amidine derivatives which are inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | disclosed |
| WO-2001046171-A1 | AMIDINE DERIVATIVES WHICH ARE INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001046170-A1 | AMIDINE DERIVATIVES WHICH ARE INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
| US-5547966-A | Aryl urea and related compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-08-20 | — | — | US | disclosed |
| EP-0656350-A1 | Biaryl urea and related compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118357-A1 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | EGFR, ERBB3, FGFR3 | ALDH1A1 2287/4885MAPT 4833/4885CTSV 3296/4885 |
| US-20020137736-A1 | N-(4-methoxy-3-((methylamino)methyl)phenyl)-2 -thiophenecarboximidamide, for example; nitric oxide synthase inhibitors; treating hypoxia, ischemia, stroke, Parkinson's disease, anxiety, schizophrenia, migraine and pain | OPRM1, HIF1AN, MAOB | ALDH1A1 784/4885MAPT 986/4885CTSV 4252/4885 |
| US-20120316230-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | EGFR, ERBB3, FGFR3 | ALDH1A1 2351/4885MAPT 4827/4885CTSV 3243/4885 |
| US-20020137750-A1 | Amidine derivatives which are inhibitors of nitric oxide synthase | NOS1, NOS2, NOS3 | ALDH1A1 449/4885MAPT 1559/4885CTSV 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.